The NIHR Cambridge CRF delivers early phase experimental medicine and clinical translational research, including industry-collaborative and industry-contracted studies in all health specialties.
We have developed long-standing relationships with many campus research teams, supporting the development of their ideas from proof-of-concept studies through to clinical translation, commercialisation and regulatory approval. Innovations such as alemtuzumab therapy for multiple sclerosis, the artificial pancreas for treatment of diabetes and the Cytosponge device for diagnosis of oesophageal pre-cancer and are amongst the many life-changing advances made possible through our facility.
If you are interested in running a study at the NIHR Cambridge CRF, please contact us to discuss your needs first before applying formally. We are very happy to offer preliminary meetings and tours. We can help with assessing feasibility, advising on costs and navigating the regulatory landscape.
All studies require a local Principal Investigator and named clinicians who will provide medical cover.
To discuss your study, please contact our Director of Operations via CRF Enquiries email.
For general enquiries about our facilities please contact our Business and Operations Manager via CRF Enquiries email.
Study Application Process
The Cambridge Clinical Research Centre (CCRC) is the overarching organisation that includes all of our clinical research facilities. The CCRC Scientific Advisory Board (SAB) reviews all research applications. The SAB convenes monthly, on the first Thursday of the month; the dates and deadlines for submission are shown below.
To register a new application, please download and complete our application form and send it to email@example.com
We will require a study protocol and as much other supporting documentation as you have available at this stage. Before the study starts we will require evidence of approval by an ethics committee, the MHRA (if applicable) and confirmation of capacity and capability from the CUH R&D office.
Once your submission has been discussed at the SAB, you will receive written notification of the outcome within a week.
Scientific Advisory Board Meeting Dates
08 December 2022
12 January 2023
09 February 2023
16 March 2023
13 April 2023
11 May 2023
15 June 2023
13 July 2023
17 August 2023
14 September 2023
12 October 2023
16 November 2023
SAB Meeting Date
05 January 2023
02 February 2023
02 March 2023
06 April 2023
04 May 2023
01 June 2023
13 July 2023
03 August 2023
07 September 2023
05 October 2023
02 November 2023
07 December 2023
Communicating your Research
NIHR Statement and Acknowledgement
When communicating your research through research publications, conference posters or presentations or via other means, it is important to include full and accurate attribution to the organisations that fund and support the underpinning research so they can be reported to funders and beyond. We request that you use the following statements.
For further guidance, please send an email to firstname.lastname@example.org
Statement (Including Funder and Disclaimer)
This is a summary of independent research funded by [name of research funder] and carried out at the National Institute for Health and Care Research (NIHR) Cambridge Clinical Research Facility (CRF). The views expressed are those of the author(s) and not necessarily those of the [name of the research funder], the NIHR or the Department of Health and Social Care.
Acknowledgement only (for use within a broader set of acknowledgements/disclaimers)
The research was carried out at the National Institute for Health and Care Research (NIHR) Cambridge Clinical Research Facility (CRF).
In our annual reports to the NIHR we are obliged to include outcomes from work conducted in our CRF.
Please send details of all peer-reviewed publications, other outputs and impacts to: email@example.com
The CCRC applies the Research and Development policies and procedures of Cambridge University Hospitals NHS Foundation Trust, which are available on the CUH website.
The CCRC Operational Policy can be viewed or downloaded via this link.